Search

Contact Us

CAR-T SPECIFICITY TESTING

Screen your CAR-T Therapeutic for Off-target Binding

Evaluate the specificity of CAR-T cell therapies by screening the human membrane proteome 

Rigorous specificity testing is critical for drug and antibody development, as even minimal off-target binding can lead to serious adverse effects. Cross-reactivity assessment of cytotoxic biotherapeutics, such as CAR-T cell therapies, is imperative since off-target engagement could lead to inappropriate immune cell activation and misdirected cell killing. Since CAR-T therapies engage the target cell by binding to membrane proteins, a complete assessment of cell surface protein interactions is required to assess binding specificity.MPA CART figure_3.7.22 (2)

Comprehensive specificity profiling of novel CAR-T cell therapies is a regulatory requirement. However, CAR-T cells are not amenable to screening using traditional immunohistochemical binding assays.

Integral Molecular offers the leading solution for profiling the specificity of CAR-T cells and other antibody-based therapeutics. With a combined 7,000+ human proteins, our Membrane Proteome Array (MPA) and Secreted Proteome Library (SPL) together constitute the largest library available, allowing for comprehensive cross-reactivity assessment.

Reduce risk of toxicity by identifying potential off-target binding liabilities using the MPA

Specificity testing on the MPA early in development can de-risk CAR-T programs by selecting an scFv candidate without off-target liabilities. MPA cross-reactivity data is also widely accepted in regulatory filings for novel CAR-T cell therapies. The MPA screen is compatible with all antibodies, scFv and Fc-fusion-like compounds, as well as bicistronic CAR constructs.

LEARN MORE ABOUT THE MPA

Case Study

Cabaletta Logo

Learn how Cabaletta Bio used the MPA to screen the specificity of their novel T-cell therapeutic, and then successfully file for IND

Autoantibodies against desmoglein 3 (DSG3) cause painful mucosal blisters in mucosal pemphigus vulgaris (mPv). Cabaletta Bio developed DSG3-CAART (Chimeric AutoAntibody Receptor T cell) therapy to eliminate these autoantibodies by targeting the corresponding pool of antigen-specific B cells. To progress the clinical development, Cabaletta Bio needed to demonstrate the specificity of DSG3-CAART and document the lack of off-target interactions for their IND submission.

READ THE CASE STUDY

Contact Us

Learn more about the Membrane Proteome Array.

Comprehensive Specificity Profiling of Antibody-Based Therapeutics Using the Membrane Proteome Array

Webinar Agenda

  • Understand how Integral Molecular’s MPA is used to select leads that do not display off-target binding liabilities
  • Learn how cell-array data, such as the MPA screen, supports IND submissions either without or in conjunction with traditional tissue cross-reactivity studies
  • Discover how the MPA was used to rapidly evaluate the specificity of a novel antibody-based SARS-CoV-2 therapeutic.
WATCH THE WEBINAR
Search